Genmab — Juli 2020
-
Helsinn and MEI Pharma stated Thursday that they have discontinued a Phase III trial testing the experimental oral HDAC inhibitor pracinostat in combination with azacitidine in patients with acute myeloid leukaemia (AML) who are considered unsuitable candidates for standard intensive chemotherapy. The move comes after an interim futility analysis undertaken by the study's independent data monitoring committee indicated that it was unlikely to meet its primary endpoint of overall survivahttps://b
-
Major Shareholder Announcement
Company Announcement
Major shareholder announcement for Genmab A/S
Copenhagen, Denmark; July 3, 2020 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Société Générale S.A. has informed us that, as of July 1, 2020, Société Générale S.A. through shares and financial instruments controls the voting rights to 3,225,334 shares in Genmab A/S, which amounts to 4.94% of the share capital and voting rights in Genmab -
God morgen.
-
Det ser i hvert fald meget underligt ud.
-
Til gengæld har vi hovedårsagen til faldet 1. juli. Det var mere SG's salg end det var DDB's salg af udnyttede warrants. Man kunne på kursgrafen se at faldet tiltog fra ca kl 15. Jeg gætter på, at det er her DDB er gået i markedet og har solgt sine forholdsvis få aktier de sidste par timer.
-
Hvis der var regulære seriøse finanstilsyn til - ville dette være en oplagt case.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind